Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 71, Issue 22, Pages 2540-2551Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.02.047
Keywords
cocaine; marijuana; myocardial infarction; substance abuse; young adults
Categories
Funding
- National Institutes of Health [5T32HL094301, T32HL007604]
- Roche Diagnostics
- Abbott
- Singulex
- Prevencio
- Spectrum Dynamics
- Amarin
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Chiesi
- Eisai
- Ethicon
- Forest Laboratories
- Ironwood
- Ischemix
- Lilly
- Medtronic
- Pfizer
- Roche
- Sanofi Aventis
- Medicines Company
- Sanofi
- Gilead Sciences
- Critical Diagnostics
- Janssen
- Novartis
Ask authors/readers for more resources
BACKGROUND Substance abuse is increasingly prevalent among young adults, but data on cardiovascular outcomes remain limited. OBJECTIVES The objectives of this study were to assess the prevalence of cocaine and marijuana use in adults with their first myocardial infarction (MI) at <= 50 years and to determine its association with long-term outcomes. METHODS The study retrospectively analyzed records of patients presenting with a type 1 MI at <= 50 years at 2 academic hospitals from 2000 to 2016. Substance abuse was determined by review of records for either patient-reported substance abuse during the week before MI or substance detection on toxicology screen. Vital status was identified by the Social Security Administration's Death Master File. Cause of death was adjudicated using electronic health records and death certificates. Cox modeling was performed for survival free from all-cause and cardiovascular death. RESULTS A total of 2,097 patients had type 1 MI (mean age 44.0 +/- 5.1 years, 19.3% female, 73% white), with median follow-up of 11.2 years (interquartile range: 7.3 to 14.2 years). Use of cocaine and/or marijuana was present in 224 (10.7%) patients; cocaine in 99 (4.7%) patients, and marijuana in 125 (6.0%). Individuals with substance use had significantly lower rates of diabetes (14.7% vs. 20.4%; p = 0.05) and hyperlipidemia (45.7% vs. 60.8%; p < 0.001), but they were significantly more likely to use tobacco (70.3% vs. 49.1%; p < 0.001). The use of cocaine and/or marijuana was associated with significantly higher cardiovascular mortality (hazard ratio: 2.22; 95% confidence interval: 1.27 to 3.70; p = 0.005) and allcause mortality (hazard ratio: 1.99; 95% confidence interval: 1.35 to 2.97; p = 0.001) after adjusting for baseline covariates. CONCLUSIONS Cocaine and/or marijuana use is present in 10% of patients with an MI at age <= 50 years and is associated with worse all-cause and cardiovascular mortality. These findings reinforce current recommendations for substance use screening among young adults with an MI, and they highlight the need for counseling to prevent future adverse events. (c) 2018 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available